<p>Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy</p>

Abstract

Despite the tremendous advances in the treatment of multiple myeloma, mortality remains significant, highlighting the need for new effective strategies. In recent years, daratumumab, a novel human monoclonal antibody, binding CD38, has dramatically improved outcomes either as monotherapy or in combination with traditional regimens. Originally approved for relapsed/refractory multiple myeloma, this breakthrough medication is now being used as frontline therapy in patients with newly diagnosed multiple myeloma regardless of transplant eligibility, with trials showing promising results. Its tolerable sideeffect profile and enhanced efficacy have led to its widespread incorporation into the management of multiple myeloma and further exploration about its use in other entities such as smoldering myeloma, MGUS, MGRS and amyloidosis. This comprehensive review will discuss daratumumab's mechanism of action and safety profile, as well as research which has defined its current approved indications, and ongoing clinical investigation that will define its future.

Simultaneous trimodal single-cell measurement of transcripts, epitopes, and chromatin accessibility using TEA-seq

“…For some targets, however, more sensitive protein abundance measures allowed detection of many additional correlated CRMs. We present two examples – one of CCR2/CD192 ( Figure 4g, h ), a chemokine receptor expressed on monocytes ( Tsou et al, 2007 ), and CD38 ( Figure 4i, j ), a glycoprotein expressed on the surface of multiple immune cell types ( Ferrero and Malavasi, 2002 ), and a target of therapies for multiple myeloma ( Dima et al, 2020 ; Sanchez et al, 2016 ). In both cases, peak-to-protein correlations identified many CRMs were missed with peak-to-gene correlation alone.…”

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

“… 2 , 22 It is important to note that in patients receiving daratumumab combination therapy, neutropenia should be closely monitored for infection. 23 For patients with thrombocytopenia, it is recommended to monitor blood cells dynamically and consider blood transfusion or growth-promoting factor treatment if necessary. 9 In addition, pneumonia is a common non-haematological adverse reaction in some clinical studies.…”

“…In summary, daratumumab will cause some adverse reactions in patients, but most are mild and controllable, and its safety is acceptable. 23 …”

Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution Experience

“…The ORR in this subgroup was 80% (assessable in 10/11). So far, FDA has approved three combinations of daratumumab with traditional therapies as frontline treatment options: 1) bortezomib/melphalan/dexamethasone, and 2) lenalidomide/dexamethasone for individuals with NDMM ineligible for ASCT, whereas for individuals eligible for ASCT FDA has approved daratumumab with bortezomib/thalidomide/dexamethasone as an initial therapeutic option [12]. Interestingly, our patients with NDMM received different patterns of daratumumab-based therapy from the aforementioned, mainly due to individualized factors including insurance and cost barriers, as well as physician's preference.…”

“…Several clinical trials have already validated the e cacy and safety of daratumumab in treating relapsed/refractory MM (RRMM) as well as newly diagnosed MM (NDMM) in various combinations with traditional backbone therapies [12]. The U.S. Food and Drug Administration (FDA) rst approved daratumumab for the treatment of RRMM in 2015, followed by its approval as frontline therapy for ASCT ineligible NDMM patients in 2018 and ASCT eligible NDMM patients in 2019.…”